At ECR 2025, DeepHealth will introduce new AI-powered radiology informatics and cancer screening solutions enabled by DeepHealth OS, its pioneering cloud-native operating system, to address clinical and operational challenges.

在ECR 2025上，DeepHealth 將推出由其開創(chuàng)性的云原生操作系統(tǒng) DeepHealth OS 支持的全新 AI 驅(qū)動的放射信息學和癌癥篩查解決方案，以應對臨床和運營挑戰(zhàn)。

DeepHealth aims to bring to European customers its

DeepHealth 旨在為歐洲客戶帶來其

to redefine the traditional Picture Archiving and Communication System (PACS) with a unified workspace tailored for modern radiology, and

重新定義傳統(tǒng)的圖像存檔與通信系統(tǒng) (PACS)，打造一個專為現(xiàn)代放射學設(shè)計的統(tǒng)一工作區(qū)，并且

, an AI-powered end-to-end diagnostic SaaS solution for mammography, further embedding AI-based detection and diagnosis in interpretive workflows.

，一個用于乳腺X線攝影的端到端人工智能診斷SaaS解決方案，進一步將基于人工智能的檢測和診斷嵌入到解釋工作流程中。

DeepHealth will also showcase updates to its broader population health portfolio of clinical AI solutions supporting lung, prostate, and brain health.

DeepHealth 還將展示其支持肺部、前列腺和大腦健康的更廣泛人群健康臨床 AI 解決方案組合的更新。

To extend and scale these solutions, DeepHealth leverages strategic collaborations with leading industry players, such as enterprise imaging solutions provider TeraRecon and AI infrastructure company CARPL.ai.

為了擴展和規(guī)?；@些解決方案，DeepHealth 與行業(yè)領(lǐng)先的企業(yè)建立了戰(zhàn)略合作伙伴關(guān)系，例如企業(yè)影像解決方案提供商 TeraRecon 和 AI 基礎(chǔ)設(shè)施公司 CARPL.ai。

VIENNA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), will introduce next-generation AI-powered radiology informatics and population screening solutions at the European Congress of Radiology (ECR) 2025 in Vienna.

維也納，2025年2月26日（環(huán)球新聞社）——DeepHealth, Inc. 是一家全球領(lǐng)先的AI驅(qū)動健康信息學公司，也是RadNet, Inc.（納斯達克股票代碼：RDNT）的全資子公司，將在2025年維也納歐洲放射學大會（ECR）上推出下一代AI驅(qū)動的放射信息學和人群篩查解決方案。

With the aim of empowering breakthroughs in care enabled by imaging, DeepHealth’s suite of solutions addresses critical clinical and operational challenges experienced by healthcare providers around the world. DeepHealth’s solutions are powered by DeepHealth OS, a secure, scalable, and cloud-native operating system that integrates data across various solutions and enables interoperability with broader healthcare IT ecosystems.

為了推動影像賦能的護理突破，DeepHealth 的解決方案套件應對了全球醫(yī)療保健提供者面臨的重大臨床和運營挑戰(zhàn)。DeepHealth 的解決方案由 DeepHealth OS 提供支持，這是一個安全、可擴展且基于云原生的操作系統(tǒng)，能夠跨各種解決方案整合數(shù)據(jù)，并實現(xiàn)與更廣泛的醫(yī)療 IT 生態(tài)系統(tǒng)的互操作性。

Moreover, to enable AI adoption at scale, DeepHealth has established strategic collaborations enabling integrated solutions with ecosystem industry leaders..

此外，為了實現(xiàn)大規(guī)模的人工智能應用，DeepHealth 已經(jīng)與生態(tài)系統(tǒng)行業(yè)的領(lǐng)導者建立了戰(zhàn)略合作伙伴關(guān)系，以提供集成解決方案。

“At DeepHealth, we are harnessing the transformative power of AI to create cutting-edge solutions that are deeply rooted in real-world clinical needs,” said Kees Wesdorp, PhD, President and CEO of RadNet’s Digital Health division. “We believe that AI adoption at scale in radiology can only be achieved by embedding AI into and unifying data across clinical and operational workflows to empower radiologists and care teams that today are having to rely on disconnected devices and disparate data sources.

“在DeepHealth，我們正在利用人工智能的變革力量，開發(fā)深植于現(xiàn)實臨床需求的前沿解決方案，”RadNet數(shù)字健康部門總裁兼首席執(zhí)行官Kees Wesdorp博士表示?！拔覀冋J為，只有將人工智能嵌入到臨床和操作工作流程中，并統(tǒng)一數(shù)據(jù)，才能實現(xiàn)放射學領(lǐng)域的人工智能規(guī)?；瘧?，從而賦能放射科醫(yī)生和護理團隊，他們?nèi)缃癫坏貌灰蕾嚮ゲ幌噙B的設(shè)備和分散的數(shù)據(jù)來源?！?/p>

At ECR 2025, we are excited to showcase our next-generation radiology informatics and population screening solutions designed to enhance operational efficiency, clinical confidence, and care delivery across the radiology continuum.”.

在ECR 2025上，我們很高興展示我們下一代的放射信息學和人群篩查解決方案，這些方案旨在提高整個放射學領(lǐng)域的運營效率、臨床信心和護理質(zhì)量。

Streamlining workflows with next-generation radiology informatics solutions

利用下一代放射學信息學解決方案簡化工作流程

DeepHealth aims to bring to European customers its latest innovations that harness the power of AI to streamline operations, support higher volumes of patients, and assist radiologists and care teams in diagnosing patients faster and with greater accuracy.

DeepHealth 旨在為其歐洲客戶帶來最新的創(chuàng)新成果，利用人工智能的力量簡化操作流程、支持更多的患者量，并協(xié)助放射科醫(yī)生和護理團隊更快、更準確地診斷患者。

At ECR 2025, DeepHealth will showcase

在ECR 2025上，DeepHealth將展示

Diagnostic Suite?,

診斷套件?，

which harnesses the cloud-native capabilities of DeepHealth OS to set a new benchmark in medical imaging technology and the traditional Picture Archiving and Communication System (PACS). Diagnostic Suite delivers a unified AI-powered interpretive experience that is intended to seamlessly integrate with or replace existing RIS/PACS systems, bringing advanced capabilities to meet the evolving demands of radiologists.

它利用DeepHealth OS的云原生能力，在醫(yī)學影像技術(shù)以及傳統(tǒng)的圖像存檔和通信系統(tǒng)（PACS）中樹立了新的標桿。Diagnostic Suite提供了一個統(tǒng)一的、由人工智能驅(qū)動的解讀體驗，旨在無縫集成或替代現(xiàn)有的RIS/PACS系統(tǒng)，為放射科醫(yī)生帶來滿足不斷變化需求的先進功能。

A unified application, the diagnostic workspace brings together worklist, patient brief, reporting, and high-speed streaming viewer technologies with advanced visualization and AI orchestration capabilities. Diagnostic Suite is cloud-native, enabling high reliability and scalability to practices of all sizes and scale..

一個統(tǒng)一的應用程序，診斷工作區(qū)將工作列表、患者簡介、報告和高速流媒體查看器技術(shù)與高級可視化和人工智能編排功能結(jié)合在一起。診斷套件是云原生的，能夠為各種規(guī)模的實踐提供高可靠性和可擴展性。

DeepHealth is also announcing upcoming updates to

DeepHealth 還宣布了即將到來的更新

, a comprehensive suite of advanced tools designed to optimize breast cancer screening and diagnosis for more efficient workflows, which will support 2D mammograms, further improving local workflow integration. DeepHealth’s 3D solution is compatible with leading OEMs and integrates seamlessly with radiologist worklists and reporting tools.

，一套全面的先進工具套件，旨在優(yōu)化乳腺癌篩查和診斷，以實現(xiàn)更高效的工作流程，該套件將支持2D乳房X光片，進一步改善本地工作流程整合。DeepHealth的3D解決方案與領(lǐng)先的原始設(shè)備制造商兼容，并能無縫集成到放射科醫(yī)生的工作列表和報告工具中。

It features clinical AI detection capabilities that automatically localize lesions and assess suspicion levels across diverse populations and dense breast tissue, enabling a 21% increase in cancer detection rate..

它具有臨床AI檢測功能，可自動定位病灶并評估不同人群和致密乳腺組織的可疑程度，從而使癌癥檢出率提高21%。

The updates will incorporate already CE-marked 2D technology to assist in the primary read and fulfill the second reader role in mammography double reading workflows.

更新將整合已獲得CE標志的2D技術(shù)，以協(xié)助初步讀取，并在乳腺X線攝影雙讀工作流程中履行第二讀取者的角色。

State-of-the-art clinical AI solutions for lung, prostate, and brain health

最先進的臨床人工智能解決方案，用于肺部、前列腺和大腦健康

DeepHealth will also showcase its latest clinical results and feature updates to its broader population health portfolio. DeepHealth’s clinical AI solutions include comprehensive, end-to-end AI-powered solutions for clinical diagnostics and high-volume screening in lung, breast, and prostate health, along with AI-driven innovations for brain health.

DeepHealth 還將展示其最新的臨床結(jié)果，并介紹其更廣泛的人口健康管理產(chǎn)品組合的功能更新。DeepHealth 的臨床 AI 解決方案包括針對肺部、乳腺和前列腺健康的全面端到端人工智能診斷和高通量篩查解決方案，以及針對腦健康的 AI 驅(qū)動創(chuàng)新。

DeepHealth’s solutions are powering screening programs for breast cancer in the US and lung cancer in Europe..

DeepHealth的解決方案正在為美國的乳腺癌和歐洲的肺癌篩查項目提供支持。

DeepHealth’s AI-powered Lung solution

DeepHealth的AI驅(qū)動肺部解決方案

is used to assist radiologists in the NHS England’s Lung Cancer Screening Program, one of the world’s largest lung cancer screening initiatives. Within this program, 76% of detected cancers were caught at earlier, more treatable stages, compared to only 29% historically (without AI).

用于協(xié)助英國國家醫(yī)療服務(wù)體系（NHS）英格蘭的肺癌篩查計劃，這是全球規(guī)模最大的肺癌篩查計劃之一。在此計劃中，76%的檢測到的癌癥是在更早期、更可治療的階段發(fā)現(xiàn)的，而歷史上（沒有人工智能的情況下）這一比例僅為29%。

The solution provides AI-powered nodule detection, reporting, and patient management for enhanced efficiency and accuracy in lung cancer diagnosis by automatically detecting and segmenting lung nodules, enabling radiologists to interpret lung CT scans more confidently and, according to a recent study, up to 42% faster..

該解決方案提供人工智能驅(qū)動的結(jié)節(jié)檢測、報告和患者管理，通過自動檢測和分割肺結(jié)節(jié)，提高肺癌診斷的效率和準確性，使放射科醫(yī)生能夠更自信地解讀肺部CT掃描，根據(jù)最近的一項研究，速度可提升高達42%。

In prostate cancer, DeepHealth’s AI-powered Prostate solution

在前列腺癌中，DeepHealth的AI驅(qū)動的前列腺解決方案

supports high-volume population health screening programs, diagnostic interpretation, and biopsy planning enabled by automated prostate segmentation, standardized reporting, and integration with most fusion biopsy systems. The solution has been shown to enable a 97% diagnostic sensitivity, up from 92% for radiologists without AI support.

支持大規(guī)模人群健康篩查項目、診斷解讀以及通過自動前列腺分割、標準化報告和與大多數(shù)融合活檢系統(tǒng)集成實現(xiàn)的活檢規(guī)劃。該解決方案已被證明可將診斷敏感性提高到97%，而沒有人工智能支持的放射科醫(yī)生僅為92%。

and recent analyses revealed a 37% reduction in workflow time for MRI read.

最近的分析顯示，MRI讀取的工作流程時間減少了37%。

Elements of DeepHealth’s portfolio are already delivering meaningful impact for patients and healthcare providers around the world, with over 800 clinical sites and more than 3,000 radiologists leveraging its current RIS, PACS, and AI solutions to deliver better care.

DeepHealth 的產(chǎn)品組合已經(jīng)在為世界各地的患者和醫(yī)療保健提供者帶來有意義的影響，目前已有 800 多個臨床站點和 3,000 多名放射科醫(yī)生利用其現(xiàn)有的 RIS、PACS 和 AI 解決方案來提供更好的護理。

At ECR 2025, DeepHealth’s portfolio of solutions

在ECR 2025上，DeepHealth的解決方案組合

Booth no. 507, X5

展位號：507，X5

About RadNet, Inc.

關(guān)于RadNet公司

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas.

RadNet, Inc. 是美國基于網(wǎng)點數(shù)量和年度影像收入的領(lǐng)先的全國性獨立固定場所診斷成像服務(wù)提供商。RadNet 擁有和/或運營一個由 399 家門診影像中心組成的網(wǎng)絡(luò)。RadNet 的市場包括亞利桑那州、加利福尼亞州、特拉華州、佛羅里達州、馬里蘭州、新澤西州、紐約州和德克薩斯州。

In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees.

此外，RadNet 還提供以 DeepHealth 品牌銷售的放射學信息技術(shù)和人工智能解決方案、遠程放射學專業(yè)服務(wù)以及其他相關(guān)產(chǎn)品和服務(wù)，服務(wù)于診斷影像行業(yè)的客戶。RadNet 與附屬的放射科醫(yī)生一起，包括全職和按日計薪的員工及技術(shù)人員在內(nèi)，共有超過 10,000 名員工。

For more information, visit .

欲了解更多信息，請訪問。

www.radnet.com

www.radnet.com

About DeepHealth

關(guān)于DeepHealth

DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health division. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health.

DeepHealth 是 RadNet, Inc.（納斯達克股票代碼：RDNT）的全資子公司，作為 RadNet 數(shù)字健康部門所有公司的傘形品牌。DeepHealth 提供由人工智能驅(qū)動的健康信息學，旨在通過影像技術(shù)推動護理領(lǐng)域的突破?；谄湔喜⒅匦旅墓緝?yōu)勢（例如，eRAD 放射信息與圖像管理系統(tǒng)及影像存檔和通信系統(tǒng)、Aidence 肺部 AI、DeepHealth 和 Kheiron 乳腺 AI 以及 Quantib 前列腺和腦部 AI），DeepHealth 利用先進的人工智能提升運營效率，并改善肺部、乳腺、前列腺和腦部健康的臨床結(jié)果。

At the heart of DeepHealth’s portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs.

DeepHealth 產(chǎn)品組合的核心是一個云原生操作系統(tǒng) —— DeepHealth OS，它統(tǒng)一了臨床和操作工作流程中的數(shù)據(jù)，并為放射學領(lǐng)域的每個人個性化了 AI 驅(qū)動的工作空間。全球數(shù)百個影像中心和放射科部門的數(shù)千名放射科醫(yī)生使用 DeepHealth 解決方案，以實現(xiàn)更早、更可靠和更高效的疾病檢測，包括在大規(guī)模癌癥篩查項目中。

DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. .

DeepHealth 的以人為本、直觀的技術(shù)旨在突破醫(yī)療保健領(lǐng)域的可能性界限。

https://deephealth.com/

https://deephealth.com/

Forward Looking Statement

前瞻性聲明

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, CARPL.ai, TeraRecon, and DeepHealth’s informatics, hardware and software product portfolios and the collaboration’s impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends.

本新聞稿包含1995年《美國私人證券訴訟改革法案》安全港條款所指的“前瞻性聲明”。前瞻性聲明包括關(guān)于RadNet、CARPL.ai、TeraRecon和DeepHealth的信息學、硬件和軟件產(chǎn)品組合能力的聲明，以及此次合作對放射學實踐和醫(yī)療工作流程的影響，這些聲明表達了我們對未來業(yè)務(wù)、未來計劃和戰(zhàn)略、預測以及預期的未來狀況、事件和趨勢的當前信念、期望和假設(shè)。

Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “l(fā)ikely,” “may,” “should,” “will” and similar references to future periods..

前瞻性陳述通?？梢酝ㄟ^以下詞語來識別：“預期”、“打算”、“計劃”、“目標”、“尋求”、“相信”、“預計”、“估計”、“期望”、“策略”、“未來”、“可能”、“應該”、“將”以及類似的指向未來時期的表述。

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.

前瞻性陳述既不是歷史事實，也不是對未來業(yè)績的保證。由于前瞻性陳述與未來有關(guān)，因此它們本質(zhì)上受到難以預測的不確定性、風險和環(huán)境變化的影響，其中許多因素是我們無法控制的。

Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements..

我們的實際結(jié)果和財務(wù)狀況可能與前瞻性陳述中所表明的有重大差異。因此，您不應過分依賴這些前瞻性陳述中的任何一項。

For media inquiries, reach out to:

媒體咨詢請聯(lián)系：

Communications Director

通訊總監(jiān)

Phone: +31 614 440971

電話：+31 614 440971

Email: andra.axente@deephealth.com

電子郵件：andra.axente@deephealth.com

Executive Vice President and Chief Financial Officer

執(zhí)行副總裁兼首席財務(wù)官

310-445-2800

310-445-2800

_______________________________

_______________________________

Not all products are regulatory cleared for use in all markets. Regulatory clearance varies by region and product. Please refer to www.deephealth.com or contact our regulatory affairs team for more information on the specific clearances applicable in your market.

并非所有產(chǎn)品都在所有市場獲得監(jiān)管批準使用。監(jiān)管批準因地區(qū)和產(chǎn)品而異。有關(guān)適用于您市場的具體批準信息，請訪問 www.deephealth.com 或聯(lián)系我們的監(jiān)管事務(wù)團隊。

SmartMammo Dx + Assure used in a safeguard review process improved cancer detection rate by 21% in a study of over 575,000 patients, showing the same benefits across racial subgroups and patients with different breast densities. Data on file.

在一項針對超過 575,000 名患者的研究中，SmartMammo Dx + Assure 在保護性審查流程中的應用使癌癥檢出率提高了 21%，并且在不同種族亞組和不同乳腺密度的患者中均顯示出相同的益處。數(shù)據(jù)存檔。

Not all products are regulatory cleared for use in all markets. Regulatory clearance varies by region and product. Please refer to www.deephealth.com or contact our regulatory affairs team for more information on the specific clearances applicable in your market.

并非所有產(chǎn)品都在所有市場獲得監(jiān)管批準。監(jiān)管批準因地區(qū)和產(chǎn)品而異。有關(guān)適用于您市場的具體批準信息，請訪問 www.deephealth.com 或聯(lián)系我們的監(jiān)管事務(wù)團隊。

DeepHealth’s lung solution (Veye Lung Nodules in Europe) is manufactured for DeepHealth by Aidence B.V.

DeepHealth的肺部解決方案（在歐洲為Veye Lung Nodules）由Aidence B.V.為DeepHealth制造。

UK Department of Health and Social Care.

英國衛(wèi)生和社會關(guān)懷部。

New lung cancer screening roll out to detect cancer sooner

推出新的肺癌篩查以更早檢測癌癥

Hempel HL et al. Higher agreement between readers with deep learning CAD for reporting pulmonary nodules on CT. Eur J Radiol Open. 2022;9:100435. doi: 10.1016/j.ejro.2022.100435.

Hempel HL 等。使用深度學習CAD報告CT上肺結(jié)節(jié)時，讀者之間的一致性更高?！稓W洲放射學開放期刊》。2022年；9：100435。doi: 10.1016/j.ejro.2022.100435。

DeepHealth’s prostate solution is manufactured as Quantib? Prostate for DeepHealth by Quantib B.V.

DeepHealth的前列腺解決方案由Quantib B.V.為DeepHealth生產(chǎn)，產(chǎn)品名為Quantib? Prostate。

Günzel et al., 2024.

岡澤爾等，2024。

相關(guān)知識

RadNet, Inc. (RDNT)：與GE醫(yī)療的戰(zhàn)略合作推動股價上漲21%
【電動車和能效亮點】Electra Vehicles將在全球科技活動上展示人工智能驅(qū)動的電池解決方案
智能篩查機器人“用心”守護健康信息安全
革新生物醫(yī)學數(shù)據(jù)共享和AI驅(qū)動的醫(yī)療解決方案
人工智能在制藥行業(yè)的10個應用案例和示例
基于人工智能的全方位健康解決方案
人工智能驅(qū)動個性化醫(yī)療：解鎖精準健康服務(wù)新篇章
【人工智能】人工智能在醫(yī)療健康中的應用以及實際案例和進展概述
彌合醫(yī)療保健公平差距：人工智能倫理和包容性健康解決方案
推動人工智能醫(yī)療器械研發(fā)上市

網(wǎng)址: DeepHealth在#ECR2025上推出了新的人工智能驅(qū)動的放射信息學和人群篩查解決方案 http://m.u1s5d6.cn/newsview1390149.html